EP1429603A4 - Labeled cells for use as an internal functional control in rare cell detection assays - Google Patents
Labeled cells for use as an internal functional control in rare cell detection assaysInfo
- Publication number
- EP1429603A4 EP1429603A4 EP02739098A EP02739098A EP1429603A4 EP 1429603 A4 EP1429603 A4 EP 1429603A4 EP 02739098 A EP02739098 A EP 02739098A EP 02739098 A EP02739098 A EP 02739098A EP 1429603 A4 EP1429603 A4 EP 1429603A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- cells
- control
- control cell
- long chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003556 assay Methods 0.000 title description 28
- 238000001514 detection method Methods 0.000 title description 19
- 238000000034 method Methods 0.000 claims abstract description 99
- 210000004027 cell Anatomy 0.000 claims description 732
- 239000000523 sample Substances 0.000 claims description 108
- 210000004369 blood Anatomy 0.000 claims description 97
- 239000008280 blood Substances 0.000 claims description 97
- 210000004881 tumor cell Anatomy 0.000 claims description 96
- 239000000427 antigen Substances 0.000 claims description 78
- 102000036639 antigens Human genes 0.000 claims description 78
- 108091007433 antigens Proteins 0.000 claims description 78
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 238000012360 testing method Methods 0.000 claims description 60
- 239000003153 chemical reaction reagent Substances 0.000 claims description 54
- 239000000975 dye Substances 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 47
- 238000004458 analytical method Methods 0.000 claims description 36
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 31
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 31
- 239000012528 membrane Substances 0.000 claims description 31
- 238000002372 labelling Methods 0.000 claims description 29
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 28
- 229920002866 paraformaldehyde Polymers 0.000 claims description 28
- 208000026310 Breast neoplasm Diseases 0.000 claims description 27
- 206010006187 Breast cancer Diseases 0.000 claims description 26
- 230000001413 cellular effect Effects 0.000 claims description 23
- 108010076876 Keratins Proteins 0.000 claims description 22
- 102000011782 Keratins Human genes 0.000 claims description 22
- 239000006249 magnetic particle Substances 0.000 claims description 22
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 21
- 239000000834 fixative Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 21
- 239000013610 patient sample Substances 0.000 claims description 20
- 238000009739 binding Methods 0.000 claims description 18
- 230000005291 magnetic effect Effects 0.000 claims description 18
- 230000027455 binding Effects 0.000 claims description 17
- 238000003860 storage Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 11
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 11
- -1 aminostyryl Chemical group 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 239000000298 carbocyanine Substances 0.000 claims description 9
- 239000007850 fluorescent dye Substances 0.000 claims description 9
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical class [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 claims description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 210000004940 nucleus Anatomy 0.000 claims description 8
- 230000003595 spectral effect Effects 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 229940043267 rhodamine b Drugs 0.000 claims description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011162 core material Substances 0.000 claims description 6
- 230000006641 stabilisation Effects 0.000 claims description 6
- 238000011105 stabilization Methods 0.000 claims description 6
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 5
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 230000007774 longterm Effects 0.000 claims description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 210000003850 cellular structure Anatomy 0.000 claims description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- 210000002288 golgi apparatus Anatomy 0.000 claims description 3
- 210000003712 lysosome Anatomy 0.000 claims description 3
- 230000001868 lysosomic effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 239000002122 magnetic nanoparticle Substances 0.000 claims description 2
- 230000008774 maternal effect Effects 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims 10
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 6
- 229940015043 glyoxal Drugs 0.000 claims 5
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 5
- 102100032187 Androgen receptor Human genes 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 108010041397 CD4 Antigens Proteins 0.000 claims 3
- 102000006395 Globulins Human genes 0.000 claims 3
- 108010044091 Globulins Proteins 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 208000000389 T-cell leukemia Diseases 0.000 claims 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 235000020256 human milk Nutrition 0.000 claims 3
- 210000004251 human milk Anatomy 0.000 claims 3
- 239000012472 biological sample Substances 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 description 49
- 239000000243 solution Substances 0.000 description 29
- 238000010186 staining Methods 0.000 description 25
- 239000011554 ferrofluid Substances 0.000 description 23
- 238000000684 flow cytometry Methods 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 22
- 229940098773 bovine serum albumin Drugs 0.000 description 22
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
- 210000000265 leukocyte Anatomy 0.000 description 21
- 239000002953 phosphate buffered saline Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 239000011324 bead Substances 0.000 description 19
- 230000002776 aggregation Effects 0.000 description 18
- 238000004220 aggregation Methods 0.000 description 18
- 239000000872 buffer Substances 0.000 description 18
- 238000005119 centrifugation Methods 0.000 description 13
- 230000008823 permeabilization Effects 0.000 description 13
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 239000006148 magnetic separator Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 238000007885 magnetic separation Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 230000009871 nonspecific binding Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000000448 cultured tumor cell Anatomy 0.000 description 5
- 239000013024 dilution buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 4
- 239000000980 acid dye Substances 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000012421 spiking Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003040 circulating cell Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 238000009607 mammography Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YPGZWUVVEWKKDQ-UHFFFAOYSA-M 4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide Chemical compound [I-].C1=CC(N(CCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCC)=CC=C1C=CC1=CC=[N+](C)C=C1 YPGZWUVVEWKKDQ-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000018732 detection of tumor cell Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000010339 medical test Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 108010053098 biotin receptor Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- GFZPJHFJZGRWMQ-UHFFFAOYSA-M diOC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1C=CC=C1N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 GFZPJHFJZGRWMQ-UHFFFAOYSA-M 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000005381 magnetic domain Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C1/00—Magnetic separation
- B03C1/005—Pretreatment specially adapted for magnetic separation
- B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
Definitions
- This invention relates to the use of pre-labeled cells as an internal functional control in cell selection and analysis procedures.
- the invention provides a single entity that can control for such diverse parameters as magnetic labeling, magnetic selection, viscosity, temperature, reagent addition, reagent activity, and operator error in procedures involving isolation of rare cells.
- the invention is useful in aspects of cell selection, including cancer screening, staging, monitoring for chemotherapy treatments, monitoring for relapse, DNA hybridization, and numerous other forms of medical diagnosis and monitoring.
- the instant invention is especially useful in rare cell separation.
- metastases i.e., multiple widespread tumor colonies established by malignant cells that detach themselves from the site of the original tumor and travel through the body, often to distant sites. If a primary tumor is detected early enough, surgery, radiation, chemotherapy, or some combination of those treatments can often eliminate it. Unfortunately, the metastatic colonies are harder to detect and eliminate and it is often impossible to treat all of them successfully. Therefore, from a clinical point of view, metastasis can be considered the conclusive event in the natural progression of cancer. Moreover, the ability to metastasize is the property that uniquely characterizes a malignant tumor. Cancer metastasis comprises the following complex series of sequential events:
- the test is performed on 10 5 to 10 6 cells purified away from interfering red blood cells.
- 5- lO lO 6 leukocytes in normal blood, this corresponds to a practical lower limit of sensitivity of one tumor cell/ 0.1 ml of blood.
- tumor cells are often genetically unstable. Accordingly, cancer cells having genetic rearrangements and sequence changes may be missed in a PCR assay as the requisite sequence complementarity between PCR primers and target sequences can be lost.
- a useful diagnostic test needs to be highly sensitive and reliably quantitative.
- Such a test should be capable of detecting the presence of a single tumor cell in one ml of blood, thus corresponding on average, to 3000-4000 total cells in circulation.
- that number of cells can indeed lead to the establishment of a tumor.
- 3000-4000 circulating cells represents 0.01% of the total cells in a tumor, then it would contain about 4xl0 7 total cells.
- a tumor containing that number of cells would not be visible by any technique currently in existence.
- a test with the sensitivity mentioned above would detect the cancer. If tumor cells were shed in some functional relationship with tumor size, then a quantitative test would be beneficial to assessing tumor burden.
- the specific binding of 0 cells may be detected in a cancer-free patient and must be discriminated from the presence of 1-100 circulating tumor cells in a patient who is undergoing relapse. With 0 cells detected, one has no way of knowing whether the reagents and or process are working. An internal / indwelling control for assessing each of the components used in the test is thus desirable. In order to have the required certainty that a test result is valid, controls at a number of essential points in the process are necessary. The first essential point that needs control is the magnetic labeling step. With so few tumor cells in the test sample, it is vital that these cells be targeted by the antibody-bearing magnetic particles.
- Another point is the magnetic selection of the magnetically labeled targets, which includes aspirating the excess liquid and non-selected cells, and the further washing of the magnetic particle/cell complexes. Still another point in the procedure is the step of labeling with antigen specific fluorescent dyes, some of which target antigen present on the cellular surface, but some of which require the permeabilization of the cellular and/or nuclear membrane. Yet another point is the enumeration of the actual target cells. As described in U.S. patent application No. 09/248,388, filed February 12, 1999, enumeration is performed by flow cytometry, but use of the system described in U.S. Patent App No. 09/381,795, filed Sept. 23, 1999 or the system described in U.S. Patent No. 5,985,153 may also be employed if desired. These patents are incorporated by references herein.
- an experimental control is the use of 'isotopic dilution' to determine yield in chemical reactions or purifications.
- a pure sample of the molecule or compound of interest is labeled with a radioactive isotope of one of the atoms in the molecule.
- a known amount of the isotopically labeled compound is added to starting material and the chemical reaction or isolation procedure is run.
- the percentage of isotopically labeled compound is calculated.
- the comparison between the original starting materials and the final product allows a calculation of the yield or percentage recovery of the starting material.
- This type of control also allows for sophisticated analysis of which steps in a process result in the loss of product or low yields.
- the traditional controls for immunophenotyping of cells are isotype controls.
- an isotype control the test is run using a monoclonal antibody of the same isotype, same species, but directed against an irrelevant antigen.
- the monoclonal antibody on the magnetic particle is directed against the epithelial cell adhesion molecule (EpCAM).
- EpCAM epithelial cell adhesion molecule
- the clone used in the examples in this specification is a mouse antibody IgGl ⁇ .
- the traditional isotype control for this particle should be a magnetic particle prepared identically, only now the particle is labeled with a mouse antibody IgGl ⁇ , directed against an antigen that does not appear in humans, such as keyhole limpet hemocyanin (KLH).
- KLH keyhole limpet hemocyanin
- the IgGlK monoclonal antibody directed against the leukocyte antigen CD45 is labeled with fluorescein isothiocyanate (F ⁇ TC).
- F ⁇ TC fluorescein isothiocyanate
- the traditional isotype control is a FTTC-labeled monoclonal IgGlK antibody directed against an antigen which is not expressed in humans, such as KLH. Cells selected after magnetic separation and stained with this FTTC-labeled isotype antibody determine the background staining in the FIT C channel.
- the monoclonal antibody directed against the cytokeratins 4, 5, 6, 8, 10, 13, and 18 is labeled with phycoerythin (PE).
- PE phycoerythin
- This antibody is a murine monoclonal antibody, IgGl ⁇ .
- the traditional isotype control is a PE-Iabeled monoclonal IgGlK antibody directed against an antigen that does not appear in humans, such as KLH. Cells selected after magnetic separation and stained with this PE-labeled isotype antibody determine the background staining in the PE channel.
- all the antibodies in the system would be identical to those in the patient sample, except for the specificity. Cell selection with these reagents would be run side-by-side with a patient sample, using an identical aliquot of patient blood.
- the results would show a population of cells and the gates for the detection of tumor cells [FTTC-, PE+] can be selected.
- an additional blood sample free of tumor cells, would be run using the isotype control magnetic particle, the CD45-FTTC and the isotype control PE.
- the FTTC[+] cells would be the non-specifically selected leukocytes.
- the FTTC[+], PE[+] cells would be the non-specifically selected and the non-specifically staining cells.
- Cells that are FTTC[-], PE[+] would be non-specifically selected cells that were binding non-specifically to PE, but not to the FTTC MAb, as the isotype of both antibodies is the same. This non-specific binding is due to the fluorochrome, and not the antibody, or changes caused by the conjugation. Roughly, the same number of leukocytes would also appear in the patient sample with specific reagents, which also would have been non-specifically selected, yet specifically stained. Differential analysis effectively removes these leukocytes from the test results, offering further assurance that any "tumor cells" detected in the test are actually circulating epithelial cells and not non-specifically bound blood cells.
- a more accurate control would be to use the EpCAM FF, the CD45-FTTC, and an isotype PE MAb.
- the majority of the selected cells are non-specifically selected. These cells are recognized by the CD45-FITC MAb and can thus be enumerated and they represent the true non-specific selection by the EpCAM FF.
- the actual tumor cells will not be stained with CD45-FTTC, nor with the isotype control PE antibody. However, as the frequency is extremely low, one cannot determine whether there are actually tumor cells in the patient sample.
- the traditional isotype controls described above represent the types of controls appropriate to cell selection, they are not truly functional controls.
- the level of background varies considerably, depending on which antibody is chosen for an isotype control.
- the choice of isotype controls could be made to influence a higher or lower background threshold.
- this type of control does not account for the reagents used in the actual patient test. For example, the anti-cytokeratin antibody in the patient test may have been inadvertently omitted from the test mixture. This mistake would be undetected by the isotype control.
- this type of isotype control can be used for small blood samples, which require 50-150 ⁇ l of blood.
- beads as a control is well known in the art and has a clear advantage as there is no chance of mistaking a bead for a cell during the analysis of the test. Beads also store well and can be reproducibly manufactured, and have the added benefit that they can be used to accurately determine the volume of a sample. As described by Stewart et al, Cytometry 2(4): 238-243 (1982), the use of a known quantity of fluorescent beads overcomes the common problem of determining the sample volume actually analyzed by a flow cytometer. However, the use of beads as a control has limitations. Beads can be extremely sturdy, and as such unaffected by numerous conditions that would destroy a cell, thus limiting their usefulness as a control against operator error.
- Sensitivity of the bead to conditions such as temperature, pH, and isotonic strength should be similar to that of an actual cell.
- the engineering and manufacturing considerations for forming such a bead with the appropriate antigens, antigen density, and dyes to provide a control for the cell selection would be difficult. Not only must the bead have the appropriate antigens, they must be accessible under conditions similar to that of an actual cell. For example, steric factors and binding constants must be taken into consideration. Finally, beads are solid objects, not affected by the permeabilization reactions, limiting their usefulness as a control at that crucial step.
- Some examples include Streck Laboratories Cell-Chex® and Chem-Chex reagents, R&D Systems R&D Retic reagents, BeckmanCoulter Cyto-Trol® control cells, and BioErgonomics FluoroTroI® line of stabilized leukocytes.
- control cells described in the above-mentioned patents and the various commercially available reagent lines offer many forms of stabilized cells for cell procedures, the methods and reagents described would only be able to provide external controls for cell selection and analysis procedure. None would provide a suitable internal control for the selection and enumeration of rare cells, such as circulating tumor cells.
- the stability of the cells is limited to 14-30 days. In those cases where there is longer stability, the cells have been lyophilized, which increases shelf life, but may decrease reproducibility, due to inadequate reconstitution.
- If one were to use cells as an internal, positive control for rare cell selection many problems are presented. For example, how can the cells be obtained? How can the control cells be differentiable from the target cells? How can one prove that the control cells behave similarly to the target cells? How can the cells be used to control the experiment? Use, reproducibility, and efficacy are essential concerns regarding the use of cells as an internal positive control for cell selection, all of which are addressed herein below.
- control cells are added directly to a patient's whole blood sample before the sample is processed. The number of the control cells detected after the patient sample is analyzed and the fluorescent characteristics of the control cells as determined via the analytical platform to confirm that the reagents are working properly and indicate that the patient sample has been processed accurately.
- the breast cancer cell line SKBR-3 has been successfully stabilized for use as control cells.
- the cells may be fluorescently labeled with the lipophyllic membrane dye, 3,3'-dihexadecycloxacarbocyanine perchlorate (DiOC 16 (3)), (DiOC ⁇ 8 (5)), or other dyes and labels such that the control cells can be clearly discriminated from a "true" tumor cell.
- These SKBR-3 cells have certain features that enhance their use as control cells in the selection of tumor cells, including: 1. They express the epithelial cell adhesion molecule (EpCAM) antigen and are selected from blood by magnetic particles coated with EpCAM MAb;
- EpCAM epithelial cell adhesion molecule
- the membranes of the control cells are per eabilized by the permeabilization reagent
- control cells express intracellular cytokeratins and are identified by a fluorescently labeled anticytokeratin MAb;
- control cells do not express CD45 antigen and should not stain with the fluorescently labeled anti-CD45 antibody; and 5.
- the control cells have a nucleus and should stain with a fluorescent compound staining the nucleus.
- the recovery of the control cells accurately reflects the recovery of circulating tumor cells in patient samples. Although it impossible to prove that control cells behave exactly like a circulating epithelial tumor cell, it can be shown in that the magnetic separation technique described found no significant difference in recovery of cultured tumor cells, whether or not they had a high or low antigen density.
- the antigen density range of cell lines available is similar to the range of tumor cells found in cancer patients.
- stabilized cells for use as an internal control in methods for isolating and identifying rare cells.
- the control cells of the invention have determinants in common with rare cells, and are membrane labeled.
- the cellular components and antigenic moieties of the control cell have been stabilized for a period up to at least six months by exposure to fixative.
- the cells may be redundantly membrane labeled with at least two fluorescent labels having the same spectral properties.
- a process for making the stabilized internal control cells includes the following steps: i) redundantly labeling the control cell with at least two fluorescent labels having the same spectral properties; ii) contacting the labeled cells with a cell fixative, the fixative effecting stabilization of both cellular structure and antigenic moieties present on said control cell; and iii) subsequently removing the excess fixative to promote long-term storage of said control cells, said control cells being physically and biologically stable for a period up to at least six months.
- the rare cell is a cancer cell and the disease state is cancer.
- An exemplary method the invention includes the following steps: i) obtaining a blood sample from a test subject, the sample comprising a mixed cell population suspected of containing said rare cells; ii) preparing an immunomagnetic sample wherein the blood sample is mixed with magnetic particles coupled to a ligand which reacts specifically with a determinant of the rare cells, to the substantial exclusion of other sample components; iii) contacting the immunomagnetic sample with at least one reagent which labels a determinant of the rare cells; and iv) analyzing the labeled rare cells to determine the presence and number of any rare cells in the immunomagnetic sample, the greater the number of rare cells present in said sample, the greater the severity of the disease state, the improvement comprising the addition of a stabilized cell for use
- kits which facilitates the practice of the methods described herein.
- An exemplary kit for isolating circulating epithelial (tumor) cells in human blood includes: coated magnetic nanoparticles comprised of magnetic core material, a protein base coating material, and an antibody that binds specifically to epithelial-derived cells, the antibody being coupled, directly or indirectly, to said base coating material; at least one antibody having binding specificity to the epithelial derived tumor cells, which is labeled with a detectable label; and stabilized control cells that are labeled with a detectable label and which bear at least one surface antigen in common with the rare cells of interest.
- the kit may optionally contain permeabilizing reagents, wash and/or dilution buffers, aggregation reagents, additional detectably labeled antibodies or additional cell specific dyes.
- a further aspect of the invention is a storage medium of similar density to the control cells, i.e. a neutral buoyant density medium. This will insure that the control cells remain well dispersed so that they may be pipetted with greater precision.
- Figures 1A-1C Flow cytometric analysis of control cells.
- Fig. 2 Stability of fixed SKBR-3 cells (pre-labeled with HER2neu-Cy2TM MAb) in excess paraformaldehyde (PFA) or no PFA, compared to fresh cells.
- Fig. 3 Antigen density, as measured by mean fluorescence intensity in 18 patients with breast cancer.
- Fig. 4a-e Cell Spotter® analysis of EpCAM ferrofluid selected cells from a prostate cancer patient's blood.
- Fig. 5a-d Flow cytometric analysis of EpCAM ferrofluid selected cells from blood, with and without a tumor cell spike.
- Fig. 6a-d Flow cytometric analysis of EpCAM ferrofluid selected cells from blood, without a tumor cell spike.
- Fig. 7a-d Flow cytometric analysis of EpCAM ferrofluid selected cells from blood, spiked with tumor cells.
- target bioentities refers to a variety of materials of biological or medical interest. Examples include hormones, proteins, peptides, Iectins, oligonucleotides, drugs, chemical substances, nucleic acid molecules, (e.g., RNA and/or DNA) and particulate analytes of biological origin, which include bioparticles such as cells, viruses, bacteria and the like.
- nucleic acid molecules e.g., RNA and/or DNA
- particulate analytes of biological origin which include bioparticles such as cells, viruses, bacteria and the like.
- RNA and/or DNA particulate analytes of biological origin
- RNA and/or DNA particulate analytes of biological origin, which include bioparticles such as cells, viruses, bacteria and the like.
- IR cells refers to a variety of cells, microorganisms, bacteria, and the like.
- circulating cancer cells, virally infected cells, or fetal cells in maternal circulation may be efficiently isolated from non- target cells and/or other bioentities, using the compositions, methods, and kits of the present invention.
- biological specimen includes, without limitation, cell-containing bodily fluids, peripheral blood, bone marrow aspirates, bone marrow biopsies, lymphoid tissue biopsies, tissue homogenates, fine needle aspirates, serosal fluids, spinal fluids, skin, mucosa, nipple aspirates, and any other source of cells that is obtainable from a human subject.
- An exemplary tissue homogenate may be obtained from the sentinel node in a breast cancer patient.
- Biological specimens may also be obtained from treated water samples and food products.
- determinant when used in reference to any of the foregoing target bioentities, may be specifically bound by a biospecific ligand or a biospecific reagent, and refers to that portion of the target bioentity involved in, and responsible for, selective binding to a specific binding substance, the presence of which is required for selective binding to occur.
- determinants are molecular contact regions on target bioentities that are recognized by receptors in specific binding pair reactions.
- specific binding pair refers to any substance that selectively recognizes and interacts with a determinant on a target bioentity.
- Specific binding pairs include antigen-antibody, receptor-hormone, receptor-ligand, agonist- antagonist, lectin-carbohydrate, nucleic acid (RNA or DNA) hybridizing sequences, Fc receptor or mouse IgG-protein A, avidin-biotin, streptavidin-biotin and virus-receptor interactions.
- Various other determinant-specific binding substance combinations are contemplated for use in practicing the methods of this invention, such as will be apparent to those skilled in the art.
- the term "antibody” as used herein includes immunoglobulins, monoclonal or polyclonal antibodies, immunoreactive immunoglobulin fragments, and single chain antibodies. Also contemplated for use in the invention are peptides, oligonucleotides or a combination thereof which specifically recognize determinants with specificity similar to traditionally generated antibodies.
- detectable label is used to herein to refer to any substance whose detection or measurement, either directly or indirectly, by physical or chemical means, is indicative of the presence of the target bioentity in a test sample.
- useful detectable labels include, but are not limited to molecules or ions directly or indirectly detectable based on light absorbance, fluorescence, reflectivity, light scatter, phosphorescence, or luminescence properties; molecules or ions detectable by their radioactive properties; molecules or ions detectable by their nuclear magnetic resonance or paramagnetic properties.
- cell specific dyes describes a free or unconjugated dye, which stains a specific cellular element (e.g. nuclear stains differentiating DNA and RNA), or a dye conjugated to a binder, which selectively binds to and stains a specific cellular receptor.
- the phrase "to the substantial exclusion of refers to the specificity of the binding reaction between the biospecific ligand or biospecific reagent and its corresponding target determinant. Biospecific ligands and reagents have specific binding activity for their target determinant yet may also exhibit a low level of non-specific binding to other sample components.
- lung stage cancer refers to those cancers that have been clinically determined to be organ-confined. Also included are tumors too small to be detected by conventional methods, such as mammography for breast cancer patients, or X- rays for lung cancer patients. While mammography can detect tumors having approximately 2 x 10 8 cells, the methods of the present invention should enable detection of circulating cancer cells from tumors approximating this size or smaller.
- enrichment as used herein- refers to increasing the ratio of the target cells to total cells in a biological sample. In cases where peripheral blood is used as the starting materials, red cells are not counted when assessing the extent of enrichment.
- circulating epithelial cells may be enriched relative to leukocytes to the extent of at least 2,500 fold, more preferably 5,000 fold, and most preferably 10,000 fold.
- test refers to a procedure or a series of procedures using known reagents for the purpose of determining the absence or presence of a target bioentity in a biological specimen.
- An assay may include quantitated reagents and established protocols to assess the presence, absence, or activity of a biological entity.
- test system is used herein to signify the entire procedure using known reagents for determining the absence or presence of a target bioentity in a biological specimen. The test is performed by an operator with the system that includes at least one assay, the hardware and software (if any) used to perform the assay(s), and the analysis of the results of the assay(s).
- standards are used herein to signify materials which are used to set up and/or calibrate an instrument and which do not require additional preparation.
- standards have specific properties similar to the analyte, e.g., a microbead population having a specific intensity and wavelength to set the analysis range of an instrument and/or quantify fluorescence intensity.
- control describes a substance or mixture of known composition with properties that fall within pre-determined ranges and is designed to undergo the same processing protocols as the analyte or substance of interest to ensure that reagents and/or cell preparations are working as expected.
- isotype control refers to the use of a monoclonal antibody of the same isotype, same species, but directed against an irrelevant antigen. Isotype controls are widely used to set the discriminatory level between non-specific background and positive fluorescent staining.
- external control refers to any substance or mixture of known composition that is subjected to the same conditions as the test substance within an assay or a test system for the purpose of establishing a basis for comparison with the test substance.
- An external control may be a positive or a negative control and multiple external controls may be used within one test system.
- internal control refers to any substance or mixture of known composition that is added to or mixed with a test substance within a test system for establishing a basis for comparison with the test substance.
- the two substances undergo identical conditions within the test system, providing an explicit measure of the efficacy of the entire test system.
- a quantified and appropriately labeled functional control cell aliquot added to a patient blood sample provides not only an internal control of the test system, but also a quantifiable and analytical control of cell recovery in the test system.
- negative control refers to an internal or external control substance that behaves in a manner generally similar to the target bioentity. However, the negative control substance lacks at least one of the characteristic determinants that distinguish the target bioentity from other biological entities, such that at the end of the assay or the test procedure, the negative control substance is not detected.
- positive control refers to an internal or external control substance which behaves in a manner similar to the target bioentity, and includes the characteristic determinants which are used in the assay or test procedure to distinguish the target bioentity from other biological entities. In fact, in some cases a positive control actually functions as the target bioentity. A positive control put through an assay or a test system is present at the end of the assay or the test procedure, thus assuring that if the positive control had been the target bioentity, it would have been detected. Note that it is only upon analysis of the results that the positive control is "separated” from the target substance.
- the term "fixed” as used herein refers to the practice of adding a chemical compound for preserving cell structure for analysis.
- Traditional fixing agents include, but are not limited to, paraformaldehyde, glutaraldehyde, methanol, or other alcohols. Although a fixed cell remains physically stable for an extended period, some cellular antigens may not be preserved, which is detrimental to any process (staining, separation, labeling, etc.) which requires antigen integrity.
- the term "stabilized" is used herein to signify a fixed cell that maintains antigen integrity in a reproducible manner over time. Therefore, a stabilized cell can be successfully and reproducibly stained, separated, or labeled in an antigen-specific reaction.
- the preferred magnetic particles or ferrofluids for use in carrying out this invention are particles that behave as colloids. Such particles are characterized by their sub-micron particle size, which is generally less than about 200 nanometers (nm), and their resistance to gravitational separation from solution for extended periods of time. In addition to the many other advantages, this size range makes them essentially invisible to optical analytical techniques commonly applied to cell analysis. Particles within the range of 90- 150nm and having between 70-90% magnetic mass are contemplated for use in the present invention.
- Suitable magnetic particles are composed of a crystalline core of superparamagnetic material surrounded by coating molecules which are bonded, e.g., physically absorbed or covalently attached, to the magnetic core and which confer stabilizing colloidal properties.
- the coating material should preferably be applied in an amount effective to prevent non-specific interactions between biological macromolecules found in the sample and the magnetic cores.
- biological macromolecules may include sialic acid residues on the surface of non-target cells, lectins, glycoproteins and other membrane components.
- the coating material should contain as high a magnetic mass/nanoparticle ratio as possible.
- the size of the magnetic crystals comprising the core is sufficiently small that they do not contain a complete magnetic domain.
- Magnetic particles having the above-described properties can be prepared by modification of base materials described in U.S. Patent No. 5,698,271.
- magnetic particles coated with anti-EpCAM antibody are prepared as described in U.S. Application No. 09/248,388. Magnetic particles coated with anti-epithelial antibodies sold by other companies, including Miltenyi Biotec and Dynal can also be used in these rare cell isolation procedures.
- the following table shows exemplary cell lines that can be used as a source of control cells. Each of these cell lines expresses surface markers that are specific to the disease, making them useful candidates for control cells.
- tumor cell lines may be used as a source of control cells provided they have surface markers and the capability of accepting additional labels.
- the rare cell assay, as applied to the determination of circulating tumor cells, involves the selection and detection of cancer cells present in blood. Tumor cells in patients with epithelial derived tumors can be present in frequencies below one cell per ml of blood. That is why it is preferred to process 5- 10ml of blood per assay.
- An exemplary assay of the invention consists of several steps:
- Two types of controls may be used.
- One control is external, in which known number of epithelial tumor cells are added to a normal control blood sample, which is then assayed along with the patient sample.
- the external control assay allows one to determine the recovery of spiked tumor cells, which should fall within set specifications. It may be difficult to utilize such an assay because the laboratory may not have cells to spike into blood, or may not be able to obtain a normal sample of 5-10ml blood.
- external controls may not be ideal, as they do not control random operator errors with respect to addition of reagents and skipping of any reagent(s). In such cases, the best control will be internal, where the number of epithelial cells spiked into a patient sample can be recovered and detected.
- the spiked control cells In order to differentiate a large number of spiked control cells from a smaller number of actual tumor cells present in the patient blood, the spiked control cells must be pre-labeled with a specific fluorescent dye or other marker with the high labeling efficiency (fewer than one unlabeled cell in 10 5 ). More than one type of label may be used to further ensure that no unlabeled control cells are present. However, such redundant labeling is not normally needed. The presence of this specific label on cells during analysis will indicate a control cell. To utilize such a test, it is necessary to provide positive labeled controls along with the assay. Cultured tumor cells with the appropriate markers can be used as positive controls but they are not stable for more than 24 hours. Therefore, the positive labeled control cells should be pre-labeled and stabilized for long-term use. The specific antigens present on positive controls must also be preserved during the pre-labeling and remain preserved under suitable storage conditions.
- the number of control cells recovered at the end of the procedure conveys certain information to the analyst. It ensures that the test was performed correctly and that the reagents and systems were working properly.
- the recovery of tumor cells from whole blood does not describe the use of control cells.
- cultured spiked control cells recoveries of the spiked cells range from 60- 95%. Cells may be lost at numerous steps in the procedure, including separation, washing, resuspension, and transferring of the sample into the analysis platform, as well as the efficiency of the analysis platform.
- the control cells described in the present application are modified cells chosen from among these cell lines.
- the control cells' antigen densities also fall in the range of antigen densities found in actual breast cancer patients.
- the controlled aggregation technique described in the '515 application is used to bring recovery of low antigen density tumor cells up into the same range as the cells with the higher antigen density.
- the recovery of control cells and patient tumor cells should be comparable, even if the tumor cells in the patient have a low level of antigen density.
- control cells and methods of use thereof of the present invention is that if a reasonable number of control cells are recovered with the appropriate fluorescent characteristics, it cannot be disputed that when epithelial cells are recovered from a patient blood sample, they are anything but epithelial cells. Except for a few obscure diseases, sources of circulating epithelial cells are those released from tumors.
- the design of the antibodies used effectively eliminates non-specific binding, to such an extent that tumor cell counts in the single digits can be seen amongst the 5-10xl0 7 leukocytes in a 10ml blood sample. However, accuracy of this test can be enhanced via the use of a control to confirm that the reagents and the process are working correctly.
- control cells acting as an internal positive control validates the test method and results.
- the following examples further describe in some detail the process of using the control cells of this invention.
- Several preferred embodiments for practicing the methods of the invention are also set forth. These examples are intended to illustrate, rather than limit the invention. Although these examples show the effective use of control cells in the selection of circulating tumor cells, it should be evident to one skilled in the art that with the proper choice of antibodies, cell lines, and magnetic particles, the teaching of the instant invention can be extended to the selection of other rare cells from other biological specimens.
- the positive control cells can be pre-labeled with diverse markers.
- One method entails labeling cells using a lipophilic, membrane-specific fluorescent dye.
- membrane dyes There are numerous types of membrane dyes known in the art which are available commercially. Carbocyanines are among the most strongly absorbing membrane dyes known.
- Membrane dyes label cells by binding to membrane lipids. It is important that this labeling does not prevent the antibody binding to specific epithelial antigens. The binding of the dye to cells should be essentially non-reversible, and no leakage should occur du ⁇ ng storage and test procedures.
- Another approach is to label cells using a fluorescent-antibody conjugate specific for cell surface antigens.
- a further approach entails labeling cellular components with fluorescent dyes.
- Examples of this approach include, without limitation, DAPI and Hoechst 33342 for double stranded DNA, acridine orange for DNA and RNA, various rhodamine derivatives for mitochondria and the endoplasmic reticulum, neutral red for lysosomes, or lipophilic BODTPY for golgi apparatus.
- labeling cells with a lipophilic fluorescent membrane dye is described.
- Cultured cells derived from breast cancer were used in this example.
- the SKBR-3 cells that were adhered to the flask were released with trypsin and were washed once with phosphate buffered saline (PBS) by centrifugation. The cells were washed a second time with Diluent C (Sigma, cat.
- DiOC 16 (3) 3,3'- dihexadecycloxacarbocyanine perchlorate
- a stock solution of 50 ⁇ M DiOC 16 (3) was prepared in 5% mannitol with 1% dimethyl sulfoxide. The washed cells were mixed with DiOC ! (3) solution at 1:1.
- the tube was tightly covered in aluminum foil, and the labeling was allowed to proceed at room temperature for 30 minutes with occasional mixing.
- the sample was centrifuged at 2,000rpm for 5 minutes to remove unreacted dye from the cells.
- the supernatant was aspirated and cell pellet was resuspended in PBS.
- the cells were washed again by centrifugation.
- the cell pellet was resuspended in permeabilizing solution (Immunicon part No. 6025) and adjusted to a cell concentration of lxl0 6 /ml.
- the permeabilization step enables binding of intracellular antigens by antigen-specific antibodies.
- the cells were incubated with permeabilizing solution for 15 minutes at room temperature.
- the cells were fixed to enhance stability.
- the cells were centrifuged to remove excess permeabilizing solution.
- the cell pellet was resuspended in PBS and washed once more with centrifugation.
- the cells were again resuspended in PBS at a cell concentration to lxlO 6 cells/ml.
- Paraformaldehyde (PFA) was added the cell suspension at a final concentration of 0.5%.
- the tube was covered with aluminum foil and the cells were incubated at room temperature for 2 hours with mixing. After 2 hours, the excess PFA was removed by centrifugation.
- the cell pellet was resuspended in PBS and washed twice by centrifugation.
- the cell pellet was resuspended in PBS and cell concentration was adjusted to about 1.0- 2.0xl0 5 cells/ml.
- the cells were stored in the dark at 4°C. Cells DiOC ⁇ 8 (5) and other markers using similar protocols. Protocols suitable for staining adherent cells, as known in the art, may also be used.
- the preferred dyes for preparing controls are fluorescent lipophilic dyes with a high affinity for lipophilic cell membrane components.
- the requirements for such dyes are: suitable excitation/emission spectra to minimize interference with detection dyes for target cells, efficient and uniform staining of all cells, substantially irreversible binding to the cell membrane, minimal leakage and transfer of dye on storage, optical stability to photobleaching both during long-term storage and intense irradiation by laser light.
- Membrane dyes that largely meet these requirements are exemplified collectively as long- chain lipophilic carbocyanines, indocarbocyanines and indodicarbocyanines designated by the abbreviations DiOC12(3), DiOC12(5), DiOC12(7), DiOC14(3), DiOC14(5), DiOC14(7), DiOC16(3), DiOC16(5), DiOC16(7), DiOC18(3), DiOC18(5), DiOC18(7) for carbocyanines and the corresponding carboindocyanines (Dil) and carboindodicyanines.(DiD) analogs and derivatives thereof.
- Such redundant labeling can be optionally done by concurrent or sequential addition of the second pre-labeling dye, and either before or after fixation of control cells.
- DS and SP sulfopropyl derivatives
- DilC 18(5)-DS and SP-DiOC 18(3) can also be used as membrane stains.
- lipophilic aminostyryl dyes designated as DiA dyes, e.g. 4-Di-16-ASP.
- DiA dyes e.g. 4-Di-16-ASP.
- long chain analogs of numerous fluorescent dyes e.g. C18 rhodamine B and C18-fluorescein also have high membrane affinities. Stains for other cellular organelles are also available and applicable. Most of these dyes are available from Molecular Probes, Inc., Eugene, OR, or can be synthesized by published methods (F.M. Hamer, The Cyanine Dyes and Related Compounds, Interscience, 1964).
- Control cells can also be made by labeling cell surface antigens with fluorescent antibodies with affinity for such antigens as exemplified by preparing control SKBR cells labeled with fluorescent HER81 antibody. Labeling two different cellular components also allows facile dual labeling of control cells with two structurally and spectrally different fluorophores. Redundant pre-labeling of different or the same structural cellular element gives rise to control cells that further reduce the already low probability of misclassifying a control cell as a tumor cell. For example, when single labeling a control cell, a probability exists that ⁇ 1 in 1000 will not be detectably labeled. Redundantly labeling of controls cells reduces this failure in labeling probability to ⁇ 1 in 1 million cells.
- Fig. 1 shows flow cytometric analysis of 5,000 control cells in 500 ⁇ l PBS. A threshold was set on forward light scatter and the cells were gated on forward and right angle scattering.
- Example 2 Preparation of pre-labeled control cells using an antibody conjugated to a fluorescent dye
- the SKBR-3 cultured tumor cells described in Example 1 were again used. However, the cells were pre-labeled with a Her2neu antibody conjugated to a cyanine dye. Anti-Her2neu specifically binds a surface antigen present on certain tumor cells including SKBR-3.
- the Her2neu MAb was conjugated to a Cy2TM dye using a N- hydroxysuccinimide ester of Cy2TM dye (Amersham catalog # PA22000) following the manufacturer's recommendations.
- SKBR-3 cells adhered to the flask were released with trypsin and washed twice with PBS by centrifugation. The cells were resuspended in permeabilization solution and stained with Her2neu-Cy2® dye for labeling.
- Permeabilization reagent did not have any effect on staining of cells with antibody.
- the final concentration of antibody during staining was 2 ⁇ g/ml and the concentration of cells was 1x10 cells/ml.
- the staining and permeabilization were done in the dark by covering the tube with aluminum foil for 15 minutes. After permeabilization and staining, the cells were fixed for stabilization as follows.
- the cells were centrifuged to remove excess permeabilizing solution and unreacted antibody.
- the cell pellet was resuspended and washed once more with PBS.
- the cells were again resuspended in PBS and cell concentration was adjusted to l l0 6 cells/ml.
- Five percent PFA was added to cells, resulting in a final PFA concentration of 0.5%.
- the cells were incubated in a tube covered with aluminum foil at room temperature for 2 hours with constant mixing. After two hours, the sample was divided into two tubes. One tube was stored in the dark at 4°C without removing the excess PFA.
- the excess PFA removed from the second tube by centrifugation.
- the cell pellet was resuspended in PBS and washed twice by centrifugation. After the second wash, the cell pellet was resuspended in PBS and cell concentration was adjusted to about 1.0-2.0xl0 5 cells/ml.
- the final cell suspension was stored in the dark at 4°C.
- Example 3 Stability of pre-labeled control cells.
- control cells The physical stability of control cells was observed as a function of time by determining the number of cells present in suspension using flow cytometry for cell size, presence of a nucleus, and integrity of antigens.
- Two antigens were checked for integrity, which are important in the instant invention for use as control cells.
- the first antigen was EpCAM, which is used to capture cells.
- the second antigen was cytokeratin, which is used for detection. Spiking a known number of cells into normal blood provided the antigen stability data by recovery and subsequent detection using EpCAM-ferrofluid/anti- cvtokeratin-fluorochrome.
- the stability of control cells prepared in Example 2 was examined.
- permeabilization solution Two hundred microliters of permeabilization solution was added to a 12x75mm polystyrene tube. The cell stock was mixed by vortexing and 20 ⁇ l of cells were added to the permeabilization solution tube. Then 5 ⁇ l of anti-cytokeratin conjugated to PE was added to the cells to stain the cytokeratin antigen. The cells were mixed and incubated at room temperature for 15 minutes. Three hundred microliters of PBS were added to each sample and mixed. Ten microliters of ProCOUNT nucleic acid dye (Becton Dickinson Immunocytometry Systems (BDIS), San Jose, CA) were added to sample to stain the DNA present in cells and 10,000 (lO ⁇ l) of fluorescent beads (Beckman-Coulter, catalog No.
- BDIS Becton Dickinson Immunocytometry Systems
- Biological Stability Recovery of spiked control cells from blood A known number of control cells (as determined above), PFA containing stored cells, or fresh cells in cell buffer were spiked into 1ml of plasma-depleted blood in a 12x75mm tube. Plasma-depleted blood was prepared by centrifuging blood to separate blood cells from plasma. After centrifugation, most of the plasma was removed by aspiration. Then 0.5ml of wash-dilution buffer (Immunicon catalog No. B2110) was added to the pellet. After mixing the sample, 20 ⁇ l of EpCAM ferrofluid was added to the blood sample and mixed well. The tube was placed in a magnetic separator (Immunicon catalog No. QS-012) for 10 minutes.
- Immunicon catalog No. QS-012 Magnetic separator
- the tube was taken out of the magnet and the sample mixed by vortexing, and placed back in the magnetic separator for 10 minutes for collection of magnetically labeled cells.
- the uncollected sample was aspirated and the tube was removed from the magnetic separator.
- the magnetically collected cells were resuspended in 0.75ml of wash-dilution buffer and re-separated in a magnetic separator for 10 minutes.
- the uncollected sample was discarded and the collected cells were resuspended in 200 ⁇ l of permeabilization solution after removal of the tube from the magnetic separator.
- the sample was then stained with labeled antibodies to determine the recovery of tumor cells by flow cytometry as follows.
- the magnetically collected cells were resuspended in 500 ⁇ l of wash-dilution buffer. Then lO ⁇ l of ProCOUNT nucleic acid dye and 10,000 (lO ⁇ l) of fluorescent beads (Beckman-Coulter, catalog No. 6607007) were added.
- the sample was then analyzed on a FACSCalibur flow cytometer using FLl as threshold.
- the fraction of the fluorescent beads acquired in the flow cytometer was used to determine the amount of sample analyzed by flow cytometry that was then used to calculate the recovery of spiked control cells.
- the percentage recoveries of control cells are given in the Table lb.
- Table la shows the physical stability of cells. There is no significant change in cell concentration up to 270 days (9 months) in the presence or absence of excess PFA. Changes in cell concentration from one time point to another are due to within experimental errors. There is no trend over the 270 day period. These data show that cell stability physically can be maintained by treating cells with PFA and storing them with or without excess PFA. Table lb shows the recovery of control cells as a function of time. These data are graphed in Fig. 2 and show the biological stability of control cells. The antigens present on and in the cell should be preserved for selection from blood cells and detection. The EpCAM present on the surface of control cells is used for selection of cells, which is achieved by conjugating anti-EpCAM MAb to magnetic particles.
- the binding and selection of control cells by anti-EpCAM magnetic particles is directly related to presence and preservation of EpCAM antigen on cells.
- the recovery of control cells will decrease if the EpCAM antigen is not preserved, as magnetic particles will not bind control cells.
- the control cells after selection were detected by using anti-cytokeratin conjugated to a fluorochrome.
- the cytokeratin antigen is present only in control cells and not in blood cells.
- the magnetically selected control cells will not be detected if the cytokeratin antigen is not preserved, and the recovery of control cells will be lower.
- the preservation of both EpCAM and cytokeratin antigens are essential for recovery of control cells.
- control cells The recovery of control cells was compared with fresh cells at each time point. Fresh cells were prepared on the day they were tested. As seen in Table lb, there was no significant change in recovery of fresh cells and control cells stored without excess PFA as a function of time. The recovery of control cells that were stored in the presence of excess PFA tended to decrease significantly as compared to fresh cells. This shows that the presence of PFA during cell storage damages the antigen by reacting with the exposed active sites. This study shows that exposure of PFA to cells for a limited amount of time will keep cells physically and biologically stable.
- breast cancer cells found in patients have a highly variable EpCAM antigen density that can vary over a 1-3 log range.
- the magnetic separation technique employed successfully captures a reproducible percentage of tumor cells, whether or not they have high or low antigen densities. The conclusion that can be drawn from these results is that the recovery of control cells accurately reflects the recovery of circulating tumor cells in patient samples. Biopsies of eighteen pathologically confirmed breast cancers ranging in size from
- 0.1 -2.5cm stored in saline, were finely minced with scissors and then passed through a 53 ⁇ m nylon filter (SpectraMesh, SPECTRUM, Houston, TX) to remove large cell clumps. Cells were washed in PBS/1% BSA 50mM EDTA (cell buffer), then resuspended in cell buffer. Total nucleated cell counts were performed by hemacytometer with acridine orange/ethidium bromide.
- BDIS FACS Lysing Solution
- Fig. 3 illustrates the mean fluorescence intensity of each of the tumor cells in each of the 18 breast cancer biopsies.
- the range of background staining is indicated along the vertical axis with dashed arrows.
- the ranges found for the mean fluorescence intensity for a variety of tumor cell lines Colo204 (high), SKBR-3, MCF-7, BT474, and PC3(low) are indicated on the right axis.
- Example 5 Recovery of spiked low and high EpCAM antigen density cells from blood with and without aggregation of CA-EpCAM MAb ferrofluid.
- SKBR-3 Breast carcinoma cells
- a known number of SKBR-3 or PC3 cells in cell buffer were spiked into 1ml of washed blood separately in a 12x75mm tube. Washed blood was prepared by mixing 10ml acid citrate dextrose (ACD) anticoagulated blood with 10ml wash dilution buffer (WDB Immunicon catalog No. B2110), comprised of a phosphate buffer which contains proteins to prevent any nonspecific binding of cells to the reagents. It was then centrifuged 10 minutes at 2000rpm.
- ACD acid citrate dextrose
- WDB Immunicon catalog No. B2110 wash dilution buffer
- the supernatant was aspirated, and the volume was raised up to 20ml with WDB. It was mixed and centrifuged again. The supernatant was aspirated, and the volume was raised up to 10ml, resulting in 10ml "washed blood.”
- Five hundred microliters of WDB and 15 ⁇ l of PBS containing aggregation reagent (Streptavidin Immunicon part No. 6026) were added to the sample. After mixing the sample, 25 ⁇ l of controlled aggregation epithelial cell adhesion molecule ferrofluid (CA-EpCAM FF, Immunicon part No. 6029) was added and the blood sample mixed well and incubated for 15 minutes. After incubation, the tube was placed in a quadrupole magnetic separator for 10 minutes to collect magnetically labeled cells. The magnetically isolated cells were analyzed for recovery of tumor cells by flow cytometry.
- Example 6 Control Cells in an actual patient sample with detection via the Cell Spotter®.
- WDB Five milliliters of WDB was added to a 5ml sample of blood from a patient with prostate cancer. After mixing, the blood was centrifuged for 10 minutes at 2000rpm, with the brake off. The plasma was removed by aspiration and the volume was made up to 10ml with WDB. The sample was again mixed and centrifuged. The supernatant was removed by aspiration and the volume of the washed blood was increased to 5ml with WDB. Control cells were prepared using the method described in Example 1 and then spiked into the 5ml washed blood sample. Twenty microliters of a 5.0xl0 3 cells/ml control cell stock were used, resulting in a spike of 100 control cells.
- the sample was vortexed to resuspend the magnetically collected cells, and then incubated for 15 minutes. Then 10ml of cell buffer (Immunicon part No.6013) was added and mixed by inversion. After centrifugation (1300rpm, lOmin, brake off) the liquid was aspirated down to approximately 200 ⁇ l and 20 ⁇ l 5% paraformaldehyde was added. The entire sample was pipetted into a Cell Spotter® chamber and images were acquired using filter sets for DAPI, FITC, Cy3® and Cy5®.
- Fig. 4A shows one of the Cy3® images.
- Four boxes are drawn around cytokeratin Cy3+ objects with cell-like features. Arrows are drawn from each of these boxes to panels B,C,D and E.
- the top image of each of these panels an overlay is shown from the ce-Cytokeratin-Cy3® image (green) and the DAPI image (purple); the middle image is the filter in which CD45-FTTC and DiOC 16 (3) staining can be seen; and in the bottom image the staining of Her2Cy5®.
- the boxes of which the images are shown in panels D and E contain cells that have a nucleus, stain brightly in the FITC filter (DiOC 16 (3)++) and stain positive for Her2neu- Cy5®. Both of these cells are control cells and confirm that the reagents in the test are functional. In this case, 58 of the control cells were identified which indicated that no errors were made in the sample preparation.
- the other two boxes shown in Panels B and C contain cells that have a nucleus, do not appear in the FITC filter, and do not appear in the Cy5® filter. These cells do have the properties specified for tumor cells that do not express Her2neu.
- Cells of the breast cancer cell line SKBR-3 are fixed and fluorescently labeled with the compound DiOC 16 (3).
- This compound stains cell membranes and can be excited with the argon ion laser line (488nm) commonly used in flow cytometers. The emission of the dye is detected by the same photomultiplier as is used to detect the fluorescence signals emitted by FTTC.
- the DiOC ]6 (3) stained cells were stored at a concentration of 50,000 cells/ml. In the experiment described here lOO ⁇ l of control cells ⁇ 5000 cells) were added to two 2ml ACD anticoagulated blood in a 12x75mm polystyrene tube.
- the sample was again taken out the separator, mixed, and placed back in the separator for 20 minutes. The supernatant was the removed by careful aspiration and discarded and 1ml of buffer was added to the tube. The sample was taken out of the separator, ensuring that all of the cells and ferrofluid attached to the wall of the tube were resuspended. The sample was placed back in the separator. After 10 minutes the buffer was aspirated and discarded. The tube was taken out of the separator and 200 ⁇ l of a solution permeabilizing the cell membrane, lO ⁇ l of PE labeled monoclonal antibody directed against cytokeratin and 20 ⁇ l of FITC labeled antibody were added to the tube.
- the sample was mixed again assuring that all the ferrofluid and cells attached to the wall were resuspended. After incubation for 15 minutes 2ml of buffer was added, mixed and the sample was placed back in the separator for 10 minutes. After the buffer was aspirated and discarded, the sample was taken out of the separator and 0.5ml of Disaggregation Reagent (Immunicon part No. 6027) was added. The samples were then analyzed by flow cytometry.
- Fig. 5 shows the analysis of both samples.
- the top two panels show the analysis of the sample that only contained control cells and the bottom two panels (Fig. 5c-d) show the analysis of the sample that contained both control cells as well as tumor cells.
- the forward and orthogonal light scattering dot plots are shown to the left (Fig.
- Gate R3 excludes all negative FTTC and PE events. Control cells appear in gate Rl, staining brightly with DiOC ⁇ 6 (3) (FLl) as well as staining brightly with cytokeratin PE. Leukocytes appear in gate R4, staining with CD45 FTTC but not with cytokeratin PE. Tumor cells appear in gate R2, not staining with CD45 FITC or DiOC ⁇ 6 (3), but positive for cytokeratin PE. Events that fall outside these regions are considered debris (R3-(R1+R2+R4)).
- leukocytes 2647 control cells, and 0 tumor cells were detected.
- 2353 were lost in the procedure. This loss of cells can occur at many steps, such as labeling, separation, aspiration and in this case a major contributor was the fact that approximately lOO ⁇ l was left in the tube after data acquisition on the flow cytometer (20% of the sample).
- assay development it is important to identify the steps that are most critical to the loss of cells. When the assay is used to determine whether or not a patient has cancer cells in the blood and how many cancer cells per volume unit, it is important to know whether or not the sample was accurately processed and whether or not the reagents are functioning properly.
- Example 8 Internal control cells for the circulating tumor cell assay that can be analyzed by automated cell analytical platforms
- a flow cytometer is equipped with a 488nm argon ion laser as well as a 635nm laser diode.
- an optical cell analysis instrument as described in US Patent No. 5,985,153, equipped with a 535nm laser diode as well as a 635nm laser diode could also be used for analysis.
- the combination of fluorochromes used to label the different probes to identify cancer cells in peripheral blood can be easily changed.
- the antibody recognizing the cytokeratin is still labeled with PE, and is excited with the 488nm laser line or the 535nm laser diode.
- the 535nm light source is closer to the maximum absorption peak of PE, and thus results in a better signal to noise ratio.
- the antibody recognizing leukocytes is also used to eliminate cells or events that are nonspecifically binding in this configuration.
- the CD45 antibody is labeled with allophycocyanine (APC) and is excited with the 635nm laser diode, but not with the 488nm laser line or the 535nm laser diode.
- APC allophycocyanine
- the dye that is used to stain and identify the control cells would be preferably measured in the same channel as the APC channel, provided that the control cells indeed can be separated from the leukocytes as in the previous example.
- the cells of the breast cancer cell line SKBR-3 are fixed and fluorescently labeled with the lipophilic membrane dye l,l'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanin (DiIC 18 (5), Fluka.)
- This compound stains cell membranes and can be excited with the 635nm laser diode.
- the emission of the dye is detected by the same photomultiplier as is used to detect the fluorescence signals emitted by APC.
- the DiIC ⁇ 8 (5) stained cells are used at a working concentration of Ixl0 s cells/ml.
- 50 ⁇ l of control cells 5000 cells
- 50 ⁇ l of unlabeled cells of the breast cancer cell line SKBR-3 was added containing approximately 5000 cells.
- the sample was mixed and 1.0ml of buffer, 9 ⁇ g of Aggregation Reagent and 9 ⁇ g of CA-EpCAM FF were added to the sample in that order, mixed one at a time, and placed in a magnetic separator. After 10 minutes, the sample was taken out, mixed, and placed back in the separator for another 10 minutes.
- the sample was again taken out of the separator, mixed, and placed back in the separator for 20 minutes.
- the tube was taken out of the separator, and lOO ⁇ l of a solution permeabilizing the cell membrane, lO ⁇ l of PE labeled monoclonal antibody directed against cytokeratin, and 20 ⁇ l of CD45-APC labeled antibody (Pharmingen) were added to the tube.
- the sample was mixed assuring that all the ferrofluid and cells attached to the wall were resuspended. After incubation for 15 minutes, 1ml of WDB was added, mixed and the sample placed back in the separator for 10 minutes. After the buffer was aspirated and discarded, the sample was taken out of the separator and 0.5ml of Disaggregation Reagent was added. The samples were then analyzed by flow cytometry.
- Figs. 6 and 7 show the analysis of both samples.
- Figures 6a-c show the analysis of the sample that only contained control cells and
- Figures 7a-c show the analysis of the sample that contained both control cells as well as tumor cells.
- the forward and orthogonal light scattering dot plots are shown in Figs. 6a and 7a.
- the dot plots correlating the PE signals versus FLl are shown in Figs. 6b and 7b.
- Gate Rl is indicated identifying PE[+] events.
- the arrow indicates the position of events that are indicative of non-specific fluorescing in the PE and the FLl channels.
- the PE versus APC dot plots are shown in Figs. 6c and 7c.
- Four gates are indicated. Leukocytes appear in gate R2, staining with CD45 APC, but not with cytokeratin PE. In gate R3, tumor cells appear, not staining with CD45 APC or DiIC 18 (5), but positive for cytokeratin PE.
- gate R5 the control cells appear, staining brightly with DiIC ⁇ 8 (5), as well as staining brightly with cytokeratin PE.
- the cells that appear in gate R4 may be non-specifically bound to CD45- APC, non-specifically binding leukocytes which stain with PE or possible tumor cells.
- 1144 leukocytes [R2], 2023 control cells [R5], 3 possible tumor cells [R4], and 0 tumor cells [R3] were detected. Possible tumor cells exhibit the fluorescence characteristics of labeled tumor cells, but fall outside the thresholds for tumor cells. These events always lack one feature that would confirm them as actual tumor cells. As 5000 control cells were added to the original blood sample, 2977 were lost in the procedure.
- Example 9 Storage of control cells under neutral buoyant conditions.
- a 45% BSA solution (Sigma) was diluted to 25%, 15%, 10%, and 5% in PBS.
- the gradients were prepared in a centrifuge tube as follows: First 3ml of 25% BSA was added to the empty 15ml centrifuge tube. Then 3ml of 15% BSA solution were gently layered on top of the 25% BSA solution without mixing. The 10% BSA solution was gently layered on top of 15%. The 5% BSA solution was gently layered on top of 10%. Different layers of BSA solutions can be seen clearly. Fresh SKBR-3 cultured tumor cells (2xl0 6 cells/ml) 1% BSA in PBS, were layered on top of the 5% BSA solution. The 15ml tube was centrifuged at 400g for 30 minutes, brake off.
- the major band was a wide band of cells on top of 15% BSA solution and the minor band was a much smaller band on top of 10% BSA solution.
- the minor band contained mostly dead cells.
- SKBR-3 cells (1 x 10 5 ) were added to 1ml of PBS, 15% BSA solution in a 12x75mm polystyrene tube and mixed well.
- lxlO 5 SKBR-3 cells were added to 1ml of PBS, 1% BSA solution in another 12x75mm polystyrene tube. Both tubes were centrifuged at 400g for 10 minutes. Centrifugation will bring cells down to the bottom of the tube in regular buffers. There was a cell pellet at the bottom of the 1% BSA in PBS tube.
- Example 10 Using internal controls at different cell concentrations.
- Examples 7 and 8 show using pre-labeled cells as internal controls at one particular cell concentration. Internal control at one cell concentration will show that the test was done correctly, but does not indicate the efficiency of recovery of cells at different cell concentrations.
- the number of tumor cells present in patient samples varies and may not be similar to number of control cells used. However, the recovery of spiked culture tumor cells is linear from 1 cell/ml to 5000 cells/ml of blood in the model study. But, it is not known how the recovery of control cells from patient sample behaves at various concentrations. This can be answered by spiking control cells at different concentrations to the patient sample and recovering them. It can not be achieved by using control cells with same fluorescence intensity for different concentrations. It can be achieved by using different control cells with different intensities of the same fluorescence marker or with different fluorescent markers.
- control cells can be prepared with different fluorescence markers that have different characteristic fluorescence properties and can be differentiated easily.
- two different types of control cells with difference fluorescence properties were used.
- Control cells which were used in example 7 were pre-labeled with DiOC16(3) which has fluorescence emission similar to FTTC.
- control cells which were pre-labeled with DiOC18(5) were used and they emit fluorescence similar to APC.
- FTTC emits maximum fluorescence at 519nm
- APC emits maximum fluorescence at 660nm.
- These two control cells can be differentiated easily by fluorescence microscopy, flow cytometry, or other optical analytical platforms, including that described in US Pat No. 5,985,153.
- DiOC16(3) labeled control cells can be used as high concentration (5000 cells/ml blood) control cells and
- DiOC18(5) labeled control cells can be used as low concentration (5 cells/ml blood) control cells.
- a known number of high and low control cells are spiked into patient blood and then the recovery of both high and low control cells are determined.
- the percentage recovery of both cells should be similar if the efficiency of recovery of control cells at low and high cell concentration is the same.
- the recovery of tumor cells may fall in between low and high control cell concentrations. Then it is possible to calculate the recovery of tumor cells using both low and high control cell recoveries.
- Control cells with various cell concentrations Another way of using control cells with various cell concentrations is by spiking control cells having different fluorescence intensities.
- Control cells with certain fluorescence intensity represents a particular cell populations.
- Control cells with different fluorescence intensities can be prepared by changing the labeling conditions such as the dye concentration or the staining time.
- compositions and methods of the invention can be applied to other cell types to produce internal controls for other assays.
- new methods for isolation and enrichment of circulating cells are developed, including methods for detecting the many diseases described in Application No 09/248,388 (incorporated by reference herein), there will be the need for internal controls.
- Target cells include without limitation circulating cancer cells, such as breast, prostate, colon, lung, kidney, ovarian cancers, leukemia, melanomas, gliomas, and any of the many other cancer types. Each of these has a tumor cell line that could be suitable for producing control cells.
- circulating target cells indicative of disease states such as endothelial cells, smooth muscle cells, myocardial cells can be assayed, and also require controls. These cells also have corresponding cell lines, or alternatively, can be cultured and grown to produce functional controls.
- assays for infections that result in circulating target cells such as virally infected cells (HIV), bacteria, and other microbes will require internal controls, which can be provided by the methods of this invention.
- HIV virally infected cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10179790.0A EP2280283B1 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
DK10179790.0T DK2280283T3 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/801,471 US20010018192A1 (en) | 1998-02-12 | 2001-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
US801471 | 2001-03-08 | ||
PCT/US2002/006967 WO2002077604A2 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10179790.0A Division EP2280283B1 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
EP10179790.0 Division-Into | 2010-09-26 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1429603A2 EP1429603A2 (en) | 2004-06-23 |
EP1429603A4 true EP1429603A4 (en) | 2004-08-18 |
EP1429603B1 EP1429603B1 (en) | 2010-12-01 |
Family
ID=25181182
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10179790.0A Expired - Lifetime EP2280283B1 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
EP02739098A Expired - Lifetime EP1429603B1 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10179790.0A Expired - Lifetime EP2280283B1 (en) | 2001-03-07 | 2002-03-07 | Labeled cells for use as an internal functional control in rare cell detection assays |
Country Status (11)
Country | Link |
---|---|
US (1) | US20010018192A1 (en) |
EP (2) | EP2280283B1 (en) |
JP (1) | JP2004534210A (en) |
AT (1) | ATE490466T1 (en) |
AU (1) | AU2002311773A1 (en) |
DE (1) | DE60238493D1 (en) |
DK (1) | DK2280283T3 (en) |
ES (2) | ES2527210T3 (en) |
HK (1) | HK1152378A1 (en) |
PT (1) | PT2280283E (en) |
WO (1) | WO2002077604A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7282350B2 (en) | 1998-02-12 | 2007-10-16 | Immunivest Corporation | Labeled cell sets for use as functional controls in rare cell detection assays |
DE19983691T1 (en) * | 1998-10-29 | 2001-11-29 | Cell Works Inc | Characterization of multiple markers from single cells |
US8986944B2 (en) | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
EP1481248A2 (en) * | 2002-03-01 | 2004-12-01 | Cardiff & Vale National Health service Trust Universitiy Hospital of Wales | Methods for absolute cell counting |
AU2003277153A1 (en) | 2002-09-27 | 2004-04-19 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
AU2003254755B2 (en) | 2002-10-16 | 2007-12-20 | Streck, Inc. | Method and device for collecting and preserving cells for analysis |
JP4593557B2 (en) | 2003-02-27 | 2010-12-08 | ベリデックス・リミテッド・ライアビリティ・カンパニー | Circulating tumor cells (CTC): early assessment of time to progression, survival and response to therapy in patients with metastatic cancer |
JP4629675B2 (en) * | 2003-09-18 | 2011-02-09 | ベリデックス・リミテッド・ライアビリティ・カンパニー | Programmable sample preparation and analysis system without operator |
EP1664347A1 (en) * | 2003-09-23 | 2006-06-07 | University of Missouri | Methods of synthesizing polynucleotides using thermostable enzymes |
US20050181353A1 (en) * | 2004-02-17 | 2005-08-18 | Rao Galla C. | Stabilization of cells and biological specimens for analysis |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
US20070128668A1 (en) * | 2005-12-01 | 2007-06-07 | Larry Burg | Quantitative use of tracer cells |
US8337755B2 (en) | 2006-03-13 | 2012-12-25 | Veridex, Llc | Operator independent programmable sample preparation and analysis system |
RU2429486C2 (en) | 2006-06-02 | 2011-09-20 | Пфайзер Продактс Инк. | Circulating tumour cell assay |
CN101583722A (en) | 2006-07-14 | 2009-11-18 | 阿维瓦生物科学股份有限公司 | Methods and compositions for detecting rare cells from a biological sample |
US7828968B2 (en) | 2007-08-30 | 2010-11-09 | Veridex, Llc | Method and apparatus for imaging target components in a biological sample using permanent magnets |
US8110101B2 (en) | 2007-08-30 | 2012-02-07 | Veridex, Llc | Method and apparatus for imaging target components in a biological sample using permanent magnets |
KR101604649B1 (en) * | 2007-11-27 | 2016-03-18 | 베리덱스, 엘엘씨 | Automated enumeration and characterization of circulating melanoma cells in blood |
WO2010068812A1 (en) | 2008-12-10 | 2010-06-17 | Abqmr, Inc. | Nuclear magnetic resonance apparatus, methods and associated technology |
US11634747B2 (en) * | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
DK2398912T3 (en) * | 2009-02-18 | 2017-10-30 | Streck Inc | Conservation of cell-free nucleic acids |
US20110111410A1 (en) * | 2009-11-09 | 2011-05-12 | Streck, Inc. | Stabilization of rna in intact cells within a blood sample |
US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
US20110262989A1 (en) | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
US9428547B2 (en) | 2010-04-21 | 2016-08-30 | Dna Electronics, Inc. | Compositions for isolating a target analyte from a heterogeneous sample |
US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
US9645154B2 (en) | 2010-12-24 | 2017-05-09 | Arkray, Inc. | Method for detecting cancer cell |
US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
WO2013036620A1 (en) * | 2011-09-06 | 2013-03-14 | Becton, Dickinson And Company | Methods and compositions for cytometric detection of rare target cells in a sample |
US20150056649A1 (en) * | 2012-01-13 | 2015-02-26 | Konica Minolta, Inc. | Method for quantifying cell of interest in blood, and method for evaluating system for quantifying said cell |
EP2903603A4 (en) * | 2012-09-27 | 2016-08-10 | Cynvenio Biosystems Inc | Stimulus-sensitive microparticles and methods of use |
WO2014074737A1 (en) * | 2012-11-07 | 2014-05-15 | Sandstone Diagnostics, Inc. | Methods and devices for processing samples and counting cells |
US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
US10376877B2 (en) | 2013-02-07 | 2019-08-13 | Sandstone Diagnostics, Inc. | Automated sample processing, fluid distribution, and sedimentation assay |
US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
WO2015013244A1 (en) | 2013-07-24 | 2015-01-29 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
US20160178614A1 (en) * | 2013-08-02 | 2016-06-23 | Siemens Healthcare Diagnostics Inc. | Cell-based control and method |
JP6331524B2 (en) * | 2014-03-14 | 2018-05-30 | 日立化成株式会社 | Standard cell solution |
CN104568923A (en) * | 2014-12-01 | 2015-04-29 | 浙江省肿瘤医院 | Method and kit for detecting circulating tumor cell antigens in peripheral blood through electrochemical luminescence detection |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
JP6582486B2 (en) * | 2015-03-27 | 2019-10-02 | コニカミノルタ株式会社 | Method for detecting rare cells in blood |
US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
WO2018022991A1 (en) | 2016-07-29 | 2018-02-01 | Streck, Inc. | Suspension composition for hematology analysis control |
JP6485576B2 (en) * | 2018-04-19 | 2019-03-20 | 日立化成株式会社 | Standard cell solution |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016314A1 (en) * | 1993-01-08 | 1994-07-21 | Coulter Corporation | Method of using preserved control cells in the calibration of fluorescent and light scatter measurements |
EP0608987A1 (en) * | 1993-01-26 | 1994-08-03 | Becton, Dickinson and Company | Method for detecting rare events |
US5478722A (en) * | 1991-02-17 | 1995-12-26 | The Curators Of The University Of Missouri | Preserved cell preparations for flow cytometry and immunology |
WO2000062071A1 (en) * | 1999-04-13 | 2000-10-19 | Wilex Ag | Diagnostic and therapeutic use of antibodies against the urokinase receptor |
WO2002021132A2 (en) * | 2000-09-08 | 2002-03-14 | University Of Dundee | Cell assays |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5188935A (en) * | 1984-05-31 | 1993-02-23 | Coulter Electronics, Inc. | Reagent system and method for identification, enumeration and examination of classes and subclasses of blood leukocytes |
US4795698A (en) * | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
US5597531A (en) * | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
US5187099A (en) * | 1986-10-29 | 1993-02-16 | Coulter Corporation | Control slide for immunoassay kit using a low-temperature melting paraffin |
JP2619911B2 (en) | 1988-04-08 | 1997-06-11 | 東亜医用電子株式会社 | Standard blood for reticulocyte analyzer |
US5059518A (en) * | 1988-10-20 | 1991-10-22 | Coulter Corporation | Stabilized lyophilized mammalian cells and method of making same |
US5698271A (en) * | 1989-08-22 | 1997-12-16 | Immunivest Corporation | Methods for the manufacture of magnetically responsive particles |
US5610022A (en) * | 1989-09-26 | 1997-03-11 | City Of Hope | Internal control for immunocytochemistry assay |
IE76319B1 (en) | 1990-07-23 | 1997-10-22 | Becton Dickinson Co | Preservation of cells as controls or standards in cellular analysis |
US5270208A (en) * | 1991-05-09 | 1993-12-14 | Streck Laboratories, Inc. | White blood cell hematology control |
WO1993017329A1 (en) * | 1992-02-24 | 1993-09-02 | Coulter Corporation | Suspension media for hematological composition and method for its use |
WO1993018397A1 (en) * | 1992-03-02 | 1993-09-16 | Streck Laboratories, Inc. | Reference control for use with manual and flow cytometric reticulocyte counting devices |
US5342754A (en) * | 1992-09-14 | 1994-08-30 | Coulter Corporation | Preserved, non-infectious control cell for use in the identification of a disease through blood testing |
US5763204A (en) * | 1992-09-14 | 1998-06-09 | Coulter Corporation | Preparation of preserved, non-infectious control cell for use in the identification of a disease through blood testing |
US5629933A (en) * | 1995-06-07 | 1997-05-13 | International Business Machines Corporation | Method and system for enhanced communication in a multisession packet based communication system |
JP3875754B2 (en) * | 1995-11-17 | 2007-01-31 | シスメックス株式会社 | Standard solution for flow cytometer |
US5985153A (en) * | 1996-06-07 | 1999-11-16 | Immunivest Corporation | Magnetic separation apparatus and methods employing an internal magnetic capture gradient and an external transport force |
US5968831A (en) * | 1996-10-29 | 1999-10-19 | Coulter International Corp. | Cell control used to confirm enzymatic activity |
US6753190B1 (en) * | 1998-07-01 | 2004-06-22 | Nitto Denko Corporation | Immunologic test method and immunologic test kit |
-
2001
- 2001-03-07 US US09/801,471 patent/US20010018192A1/en not_active Abandoned
-
2002
- 2002-03-07 DK DK10179790.0T patent/DK2280283T3/en active
- 2002-03-07 ES ES10179790.0T patent/ES2527210T3/en not_active Expired - Lifetime
- 2002-03-07 EP EP10179790.0A patent/EP2280283B1/en not_active Expired - Lifetime
- 2002-03-07 DE DE60238493T patent/DE60238493D1/en not_active Expired - Lifetime
- 2002-03-07 AT AT02739098T patent/ATE490466T1/en active
- 2002-03-07 JP JP2002575608A patent/JP2004534210A/en active Pending
- 2002-03-07 ES ES02739098T patent/ES2357101T3/en not_active Expired - Lifetime
- 2002-03-07 AU AU2002311773A patent/AU2002311773A1/en not_active Abandoned
- 2002-03-07 EP EP02739098A patent/EP1429603B1/en not_active Expired - Lifetime
- 2002-03-07 WO PCT/US2002/006967 patent/WO2002077604A2/en active Search and Examination
- 2002-03-07 PT PT101797900T patent/PT2280283E/en unknown
-
2011
- 2011-06-21 HK HK11106359.9A patent/HK1152378A1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478722A (en) * | 1991-02-17 | 1995-12-26 | The Curators Of The University Of Missouri | Preserved cell preparations for flow cytometry and immunology |
WO1994016314A1 (en) * | 1993-01-08 | 1994-07-21 | Coulter Corporation | Method of using preserved control cells in the calibration of fluorescent and light scatter measurements |
EP0608987A1 (en) * | 1993-01-26 | 1994-08-03 | Becton, Dickinson and Company | Method for detecting rare events |
WO2000062071A1 (en) * | 1999-04-13 | 2000-10-19 | Wilex Ag | Diagnostic and therapeutic use of antibodies against the urokinase receptor |
WO2002021132A2 (en) * | 2000-09-08 | 2002-03-14 | University Of Dundee | Cell assays |
Also Published As
Publication number | Publication date |
---|---|
EP2280283A1 (en) | 2011-02-02 |
DE60238493D1 (en) | 2011-01-13 |
DK2280283T3 (en) | 2014-11-17 |
EP1429603B1 (en) | 2010-12-01 |
JP2004534210A (en) | 2004-11-11 |
WO2002077604A3 (en) | 2004-04-01 |
AU2002311773A1 (en) | 2002-10-08 |
EP1429603A2 (en) | 2004-06-23 |
ES2527210T3 (en) | 2015-01-21 |
ES2357101T3 (en) | 2011-04-18 |
EP2280283B1 (en) | 2014-10-15 |
PT2280283E (en) | 2015-02-03 |
US20010018192A1 (en) | 2001-08-30 |
WO2002077604A2 (en) | 2002-10-03 |
ATE490466T1 (en) | 2010-12-15 |
HK1152378A1 (en) | 2012-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2280283B1 (en) | Labeled cells for use as an internal functional control in rare cell detection assays | |
US7282350B2 (en) | Labeled cell sets for use as functional controls in rare cell detection assays | |
JP5960146B2 (en) | Method and kit for detecting circulating tumor cells in pancreatic patients using multispecific capture reagents and mixed detection reagents | |
JP5265855B2 (en) | Methods and reagents for rapid and efficient isolation of circulating cancer cells | |
AU2008249153B2 (en) | Methods and reagents for the rapid and efficient isolation of circulating cancer cells | |
JP2005502863A (en) | Analysis of circulating tumor cells, fragments and debris | |
CA2587765A1 (en) | Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection | |
WO2006020936A2 (en) | A method for assessing disease states by profile analysis of isolated circulating endothelial cells | |
CA2432361C (en) | Methods and reagents for the rapid and efficient isolation of circulating cancer cells | |
AU2003200334B2 (en) | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040326 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040701 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7G 01N 33/574 B Ipc: 7G 01N 33/533 A Ipc: 7C 12N 5/00 B Ipc: 7G 01N 33/50 B |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VERIDEX, LLC |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60238493 Country of ref document: DE Date of ref document: 20110113 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2357101 Country of ref document: ES Kind code of ref document: T3 Effective date: 20110418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101201 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101201 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20110401 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110331 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101201 |
|
26N | No opposition filed |
Effective date: 20110902 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60238493 Country of ref document: DE Effective date: 20110902 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110307 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20190314 Year of fee payment: 18 Ref country code: FR Payment date: 20190313 Year of fee payment: 18 Ref country code: GB Payment date: 20190306 Year of fee payment: 18 Ref country code: IE Payment date: 20190311 Year of fee payment: 18 Ref country code: DE Payment date: 20190312 Year of fee payment: 18 Ref country code: IT Payment date: 20190326 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20190311 Year of fee payment: 18 Ref country code: BE Payment date: 20190315 Year of fee payment: 18 Ref country code: TR Payment date: 20190306 Year of fee payment: 18 Ref country code: NL Payment date: 20190313 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20190401 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60238493 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20200401 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 490466 Country of ref document: AT Kind code of ref document: T Effective date: 20200307 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200307 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200307 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200331 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201001 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200331 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20200307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200307 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20210727 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200307 |